Drug Profile

Rofecoxib topical - BriOri Biotech

Alternative Names: Relÿva

Latest Information Update: 05 May 2022

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator BriOri Biotech
Class Antirheumatics; Lactones; Non-opioid analgesics; Sulfones
Mechanism of Action Cyclo-oxygenase 2 inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

Highest Development Phases

Preclinical Osteoarthritis

Most Recent Events

02 May 2022 BriOri Biotech plans a clinical trial in Osteoarthritis in 2022 (Topical)
09 Mar 2022 BriOri Biotech has patent protection for Rofecoxib in USA
15 Feb 2022 BriOri Biotech receives patent issue notification for rofecoxib topical in the US

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com